Tesofensine for Weight Loss: The Phase 2 Hit That Never Reached the Market — Evidence Review

Tesofensine is an oral triple monoamine reuptake inhibitor — it blocks the presynaptic reuptake of serotonin, noradrenaline, and dopamine, which curbs appetite. It was developed by the Danish biotech NeuroSearch as an anti-obesity drug, and in its phase 2 trial it produced some of the largest weight-loss numbers ever reported for a pill: roughly −9.2% placebo-subtracted at the 0.5 mg dose over 24 weeks, with the trial authors suggesting it “might have the potential to produce a weight loss twice that of currently approved drugs” (Astrup 2008 Lancet^[1]). Despite that, tesofensine never reached the market for general obesity: phase 3 stalled amid cardiovascular and psychiatric safety concerns in the cautious regulatory climate that followed the withdrawal of rimonabant (Acomplia). Today it survives only as a narrow rare-disease program — Saniona’s Tesomet, which pairs tesofensine with a beta-blocker — and as a gray-market “research chemical.” This article covers what tesofensine actually is, the real phase 2 evidence, why it stalled, and what it means for patients now.

The honest summary

• Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide and not a GLP-1 drug. It raises synaptic serotonin, noradrenaline, and dopamine, which together suppress appetite. It is taken orally, once daily — unlike the injectable GLP-1 and amylin drugs.
• It is investigational and not FDA-approved. Tesofensine is not approved for obesity by the FDA, EMA, or any other major regulator. It is not legitimately available from any pharmacy. Products sold online as “tesofensine” are unregulated gray-market research chemicals.
• The phase 2 TIPO-1 data were genuinely large: at 24 weeks, tesofensine 0.25, 0.5, and 1.0 mg produced weight loss of −4.5%, −9.2%, and −10.6% over and above diet plus placebo (which itself gave −2.0%), all p < 0.0001 (Astrup 2008 Lancet^[1]). That is a real, clean dose response.
• But it never reached the market. The same trial showed a dose-dependent heart-rate increase (+7.4 bpm at 0.5 mg), and the broader program raised cardiovascular and psychiatric concerns. Phase 3 for general obesity did not proceed in the post-rimonabant regulatory environment.
• The only live program is rare-disease. Saniona repositioned tesofensine as Tesomet (tesofensine + the beta-blocker metoprolol, to blunt the heart-rate effect) for hypothalamic obesity, where a small RCT showed −6.3% placebo-subtracted weight loss with no heart-rate or blood-pressure difference vs placebo (Huynh 2022 Eur J Endocrinol^[2]).
• Magnitude context: tesofensine’s phase 2 numbers are large for a pill, but the approved injectables now go further over longer trials — semaglutide 2.4 mg reached −14.9% in STEP-1 (Wilding 2021^[3]) and tirzepatide reached −20.9% in SURMOUNT-1 (Jastreboff 2022^[4]).

What tesofensine actually is, pharmacologically

Tesofensine (development code NS2330) is a small-molecule inhibitor of the presynaptic reuptake of three monoamine neurotransmitters: serotonin, noradrenaline, and dopamine. By blocking the transporters that clear these neurotransmitters from the synapse, it raises their concentration in brain regions that regulate appetite and energy balance. The net effect in humans is appetite suppression and increased satiety — the same broad mechanism family as older centrally acting weight-loss drugs, but hitting all three monoamines rather than one or two.

That mechanism is the opposite end of the spectrum from the drugs dominating obesity care today. Semaglutide and tirzepatide are injectable peptides that act on the GLP-1 (and, for tirzepatide, GIP) receptors in the gut-brain axis. Tesofensine is an oral central-nervous-system drug. The appeal was obvious — a pill, not an injection, with phase 2 numbers that rivaled or beat the best drugs of its era. The problem, as with most centrally acting monoamine drugs, is that the same systems that govern appetite also govern heart rate, blood pressure, mood, and reward.

The phase 2 evidence: Astrup 2008 Lancet (TIPO-1)

The pivotal efficacy evidence for tesofensine in obesity is Astrup 2008^[1] (the TIPO-1 trial), a phase 2, randomised, double-blind, placebo-controlled trial published in The Lancet. It enrolled 203 adults with obesity (BMI 30–40 kg/m²) across five Danish obesity centres. After a 2-week run-in, participants were randomised to tesofensine 0.25 mg, 0.5 mg, or 1.0 mg, or placebo, once daily for 24 weeks, all on an energy-restricted diet. The primary outcome was percentage change in body weight.

The dose-response was clean and the effect size was large for an oral agent. The trial authors went as far as to conclude that tesofensine 0.5 mg “might have the potential to produce a weight loss twice that of currently approved drugs” — while explicitly cautioning that the findings “need confirmation in phase III trials.” The most common adverse events were dry mouth, nausea, constipation, hard stools, diarrhoea, and insomnia. Critically, the 1.0 mg dose and, in the wider development program, the higher exposures raised the cardiovascular and neuropsychiatric flags that would ultimately constrain the drug.

Two honesty caveats. First, on blood pressure and heart rate: at 24 weeks the 0.25 mg and 0.5 mg arms showed no significant increase in systolic or diastolic blood pressure versus placebo, but heart rate rose by 7.4 bpm in the 0.5 mg group (p = 0.0001). For a centrally acting drug intended for long-term use in people who often already have cardiovascular risk, a sustained heart-rate increase is a serious signal. Second, TIPO-1 was later the subject of an Expression of Concern published by The Lancet in 2013; readers should weigh the result in that light. The trial remains the central piece of human efficacy evidence, but it is a single phase 2 study, not a confirmed phase 3 result.

Why tesofensine never reached the market

Despite the eye-catching phase 2 numbers, tesofensine never advanced to approval for general obesity. Several forces converged. The proximate issue was the safety profile of a triple monoamine reuptake inhibitor: the dose-dependent increase in heart rate, plus concerns about blood pressure, mood, and the abuse liability inherent to dopaminergic appetite suppressants. Centrally acting weight-loss drugs carry heavy historical baggage — fenfluramine (heart-valve disease), sibutramine (withdrawn for cardiovascular events), and most consequentially rimonabant/Acomplia, withdrawn in Europe in 2008–2009 over psychiatric adverse events including depression and suicidality.

That post-rimonabant climate is the key context. Tesofensine’s pivotal phase 2 data were published in late 2008 — almost exactly as regulators were tightening their stance on any centrally acting obesity drug with the slightest cardiovascular or psychiatric signal. A pill that raised heart rate and acted on dopamine pathways was, in that environment, a hard sell for the large and expensive phase 3 cardiovascular-safety program that would have been required. NeuroSearch did not bring tesofensine to market as a general obesity therapeutic, and the asset was eventually repositioned for a far narrower use.

The second life: Saniona's Tesomet in rare disease

Tesofensine’s only live clinical program is Tesomet, developed by Saniona: a fixed combination of tesofensine 0.5 mg plus the beta-blocker metoprolol 50 mg. The metoprolol is the entire engineering insight — it is added specifically to blunt the heart-rate increase that tesofensine causes on its own, addressing the central safety liability that had stalled the drug. Rather than chasing general obesity again, Saniona aimed Tesomet at hypothalamic obesity, a rare, severe form of obesity caused by damage to the hypothalamus (often after craniopharyngioma surgery) for which there is no approved pharmacotherapy.

The supporting evidence is Huynh 2022^[2], a randomised, placebo-controlled trial of Tesomet in 21 adults with hypothalamic obesity published in the European Journal of Endocrinology. Over 24 weeks, Tesomet produced an additional mean weight change of −6.3% versus placebo (95% CI −11.3 to −1.3; p = 0.017) and increased the proportion of patients reaching ≥5% weight loss. Importantly, validating the design rationale, no significant difference in heart rate or blood pressure was seen between Tesomet and placebo — the beta-blocker appeared to do its job. Adverse events were mostly mild (sleep disturbances, dry mouth, headache), though one patient discontinued for a treatment-related exacerbation of pre-existing anxiety. It is a small, early trial in a narrow indication, not a general-obesity approval.

Magnitude: tesofensine vs the approved injectables

For an oral pill in a 24-week trial, tesofensine’s phase 2 numbers were impressive and, at the time, market-leading. But the comparison cuts both ways: the approved injectable incretin drugs run longer trials and now reach substantially greater weight loss, with cardiovascular-safety data behind them rather than cardiovascular concerns ahead of them. The pill convenience advantage is also eroding — oral GLP-1 agonists and orforglipron are advancing through their own pipelines. Tesofensine’s window as a best-in-class obesity drug has largely closed.

Where tesofensine sits in development

As of 2026, there is no FDA-approved tesofensine product for any indication. The drug is not legitimately prescribable in the United States. Its only active clinical path is the rare-disease Tesomet program in hypothalamic obesity, where the data are early and the addressable population is small. The historical cardiovascular and psychiatric signals, combined with the dominance of incretin drugs, make a revival of tesofensine as a mass-market general-obesity therapeutic unlikely. For broader context on how it fits among other non-incretin candidates, see our non-GLP-1 peptides and small molecules for fat loss evidence review and the wider peptides for weight loss overview.

What this means for patients today

Tesofensine is not a prescribable obesity drug, is not available from any legitimate pharmacy, and should not be sought from gray-market “research chemical” or peptide vendors. Anything sold online as “tesofensine” carries the usual unregulated-product risks — unverified identity, purity, and dose — compounded here by the fact that it is a potent triple monoamine reuptake inhibitor with real cardiovascular and neuropsychiatric effects. Self-dosing a drug that raises heart rate and acts on dopamine pathways, with no medical supervision and no quality control, is a genuinely dangerous proposition.

For decisions you can act on now, the relevant drugs are the approved ones: Wegovy (semaglutide 2.4 mg, STEP-1^[3]) and Zepbound (tirzepatide, SURMOUNT-1^[4]). Both have larger weight-loss effects than tesofensine’s phase 2 numbers, established cardiovascular-outcome data, and a clinician supervising the dose. If you and your clinician are weighing options, that is the conversation worth having — not an unapproved monoamine reuptake inhibitor bought from an unregulated source.

Important disclaimer. Tesofensine is an investigational drug not approved by the FDA, EMA, or any other major regulator for obesity or any other indication. The efficacy data summarised here come from a single 24-week phase 2 trial (later the subject of a 2013 Expression of Concern in The Lancet) and a small rare-disease RCT; magnitude and safety estimates are not directly comparable to the longer pivotal trials of approved drugs. This article is educational and is not medical advice or an endorsement to use any unapproved or gray-market product marketed as “tesofensine.” PMIDs were verified live against the PubMed E-utilities API on 2026-06-02.

Last verified: 2026-06-02. Next review: every 6 months, or sooner if Saniona advances the Tesomet program or a regulator acts on tesofensine.